Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Abivax (ABVX) Debt to Equity: 2023-2024

  • Abivax's Debt to Equity rose 135.81% to $0.56 in Q4 2024 from the same period last year, while for Dec 2024 it was $0.56, marking a year-over-year increase of 135.81%. This contributed to the annual value of $0.56 for FY2024, which is 135.81% up from last year.
  • Per Abivax's latest filing, its Debt to Equity stood at $0.56 for Q4 2024, which was up 135.81% from $0.24 recorded in Q4 2023.
  • Abivax's 5-year Debt to Equity high stood at $0.56 for Q4 2024, and its period low was $0.24 during Q4 2023.
  • For the 2-year period, Abivax's Debt to Equity averaged around $0.40, with its median value being $0.40 (2023).
  • Data for Abivax's Debt to Equity shows a peak YoY surged of 135.81% (in 2024) over the last 5 years.
  • Over the past 2 years, Abivax's Debt to Equity (Quarterly) stood at $0.24 in 2023, then spiked by 135.81% to $0.56 in 2024.